BDRX
Biodexa·NASDAQ
--
--(--)
--
--(--)
0.61 / 10
Underperform
Fundamental score: 0.6/10 indicating poor quality. Bullish factors include Interest coverage ratio (EBIT / Interest expense) (%) and Total operating revenue (YoY growth rate %), while concerns exist in Days sales outstanding.. Overall assessment: prudent.
Analysis Checks(3/4)
Total operating revenue (YoY growth rate %)
Value-36.32
Score2/3
Weight-27.14%
1M Return1.11%
Value-36.32
Score2/3
Weight-27.14%
1M Return1.11%
Interest coverage ratio (EBIT / Interest expense) (%)
Value-19.88
Score2/3
Weight25.34%
1M Return-1.11%
Value-19.88
Score2/3
Weight25.34%
1M Return-1.11%
Days sales outstanding
Value576.54
Score0/3
Weight112.25%
1M Return-5.18%
Value576.54
Score0/3
Weight112.25%
1M Return-5.18%
Operating revenue (YoY growth rate %)
Value-36.32
Score2/3
Weight-10.46%
1M Return0.43%
Value-36.32
Score2/3
Weight-10.46%
1M Return0.43%
Total operating revenue (YoY growth rate %)
Value-36.32
Score2/3
Weight-27.14%
1M Return1.11%
Value-36.32
Score2/3
Weight-27.14%
1M Return1.11%
Days sales outstanding
Value576.54
Score0/3
Weight112.25%
1M Return-5.18%
Value576.54
Score0/3
Weight112.25%
1M Return-5.18%
Interest coverage ratio (EBIT / Interest expense) (%)
Value-19.88
Score2/3
Weight25.34%
1M Return-1.11%
Value-19.88
Score2/3
Weight25.34%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-36.32
Score2/3
Weight-10.46%
1M Return0.43%
Value-36.32
Score2/3
Weight-10.46%
1M Return0.43%
Is BDRX fundamentally strong?
- BDRX scores 0.61/10 on fundamentals and holds a Premium valuation at present. Backed by its -38.53% ROE, 0.00% net margin, -0.13 P/E ratio, 0.07 P/B ratio, and -100.09% earnings growth, these metrics solidify its Underperform investment rating.
